Here we have further confirmation that the corporate state loves us and merely wants us to be happy, rendering aid and comfort to the morbidly obese with loving and liberal assurances that their grotesque state is a “chronic condition rather than a lifestyle disease,” as relayed to us by Democrat Party rag Axios.
Related: Are Cheerios Chemically Castrating the American Public?
Via Axios (emphasis added):
The explosive growth of Ozempic and other drugs known as GLP-1 agonists has led to greater recognition of obesity as a chronic condition rather than a lifestyle disease. But it's also sparked major concerns about the potential budget-busting costs of treating the more than 40% of Americans who are obese…
While many employers offer some coverage for obesity care, it's typically far more limited and comes with more restrictions around what they will pay for compared with other conditions.
The divide is especially stark with anti-obesity medications. 76% of employers report covering GLP-1s for diabetes, but only 27% do for weight loss, according to a 2023 survey by the International Foundation of Employee Benefit Plans.
Medicare has long had a prohibition on covering weight-loss drugs, and some states are clamping down on them.
Axios dilly-dallied on its way to the punchline, but we’ve finally got it here: the pharmaceutical industry and the various NGO “nonprofits” it bankrolls — laundering its profit motive, by such means, through the veneer of philanthropy — that demand the government pay for ludicrously overpriced drugs in the name of Equity™ and Inclusion™.
Continuing:
A group of health care organizations led by the Alliance for Women's Health and Prevention last month launched the EveryBODY campaign pushing for comprehensive coverage of obesity care, citing "misunderstandings" about obesity that it says led to insurance restrictions.
It came on the heels of the January release of an "Obesity Bill of Rights" by the National Council on Aging and National Consumers League, which calls out the medical system's disrespectful treatment of patients with obesity.
Lo and behold, the EveryBODY Campaign is bankrolled by a cornucopia of pharmaceutical industry front groups, almost universally headquartered in cushy offices right in the heart of the Swamp, Washington, D.C. — certainly without any vested interest in coercing the government into coughing up public money for expensive “weight loss” drugs produced by the likes of Novo Nordisk and Eli Lilly?
Surely?
Via PR Newswire (emphasis added):
Partners of the EveryBODY Covered campaign represent top voices on women's health and obesity and bring with them the invaluable perspectives of the diverse communities they serve. Current partners include Alliance for Aging Research, American Medical Women's Association, Black Women's Health Imperative, Cancer Support Community, Gerontological Society of America, National Association of Nurse Practitioners in Women's Health, National Caucus and Center on Black Aging, Inc., National Consumers League, Obesity Action Coalition, and Society for Women's Health Research.
As a footnote in the Axios article, it slips in a telling admission:
Eli Lilly, which makes Mounjaro for diabetes and Zepbound for obesity, is a backer of the EveryBODY covered campaign.
“Sponsored by [insert multinational pharmaceutical corporation]” — why, oh why, does that ring a bell?
